Dr. Jason Slakter discusses the future for the treatment of CNV in age-related macular degeneration (AMD). Emerging treatments seek to control various steps in the angiogenic cascade, from gene therapies that inhibit the production of VEGF to direct anti-VEGF binding agents that inhibit the effects of VEGF once the molecule is generated. Dr. Slakter also reviews agents that act outside the VEGF pathways, including those that target abnormal vascular structures to block platelet-derived growth factor (PDGF) and pigment epithelium-derived factor (PEDF), as well as novel uses of radiation, steroids, and extended release drug delivery systems.